Liza Cosca Villaruz
Universitat de València · 215 works · 6,672 citations · h-index 30
Top works
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).
- Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
- The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement
- The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
- Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis
- Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.
- IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
- Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A
- Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the L ung C ancer M utation C onsortium
- Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
- PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
- Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.
- Crizotinib in Patients With MET-Amplified NSCLC
- OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer
- The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma
- ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma
- Immunotherapy in lung cancer.
- Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study
- Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation